Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TCH346 in amyotrophic lateral sclerosis
2004-002855-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing TCH346 clinically effective dose with Placebo (2 arms). Primary endpoints: Rate of functional decline and Survival. Started Dec 2004; status: completed.
02
Drugs
omigapil
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2004-002855-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002855-15.